News

Glucose Tests Flag Diabetes in ACS Patients


 

The combination of fasting and admission plasma glucose tests was a useful initial screening tool to identify diabetes in patients with acute coronary syndrome, according to a study of 140 patients in a coronary care unit.

It has been shown that diabetes is underdiagnosed in ACS patients and is a strong predictor of future cardiovascular mortality, Dr. Onyebuchi E. Okosieme of Cardiff (Wales) University and colleagues wrote.

The oral glucose tolerance test (OGTT) is the preferred method for detecting diabetes, but the OGTT is expensive and time-consuming and “is underused in clinical practice,” according to the authors. However, the alternatives—fasting plasma glucose (FPG) and admission plasma glucose (APG)—alone often fail to detect diabetes after a cardiac event.

In this study, each patient (average age 67 years, 79% men) underwent all three methods of testing glucose levels, and were classified as having normal glucose tolerance, impaired glucose tolerance, or diabetes.

According to the results of the OGTT, 27% of this population (38 patients) had previously undiagnosed diabetes, 39% (54 patients) had previously undetected impaired glucose tolerance, and the remainder had normal glucose tolerance. When the results of the other testing methods were compared with those of the preferred method, the FPG had 82% sensitivity and 65% specificity in detecting diabetes, whereas the APG had 67% sensitivity and 83% specificity.

No conflicts of interest were reported by the researchers.

Recommended Reading

Intensive Control Offers Little Benefit for Vision
MDedge Endocrinology
Candesartan Has DIRECT Effects on Retinopathy
MDedge Endocrinology
Culturally Based Diabetes Education Aids Glycemic Control
MDedge Endocrinology
Prasugrel's Ischemic Benefit Enhanced in Diabetes
MDedge Endocrinology
Long-Term Outlook Brighter for Type 1 Patients
MDedge Endocrinology
Diabetes Medicine Guide in Spanish
MDedge Endocrinology
Aggressive Hypertension Tx in Diabetes Urged
MDedge Endocrinology
Aspirin Not Cardioprotective in Type 2 Diabetes
MDedge Endocrinology
Cardiac Stent Equal to CABG at 1-Year Follow-Up
MDedge Endocrinology
Candesartan Does Not Prevent Microalbuminuria
MDedge Endocrinology